BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update...

Serum and cerebrospinal fluid samples from the Phase 3 study of NurOwn® in ALS to be donated to the NEALS biorepository for use by the research community NEW YORK, Jan. 10, 2023 /PRNewswire/ --...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Chaim Lebovits, President and CEO, and...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Stacy Lindborg to the...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration...

Meeting expected to occur within 30 days of the FDA's receipt of the meeting request NEW YORK, Dec. 12, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer...

BrainStorm to request Type A meeting with FDA to facilitate NurOwn's advancement following receipt of a refusal to file letter regarding the company's new Biologics License Application Conference...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has received a refusal to file letter...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update...

New post-hoc analyses that account for ALSFRS-R floor effects add to the robust body of evidence supporting a clinically meaningful treatment effect with NurOwn® in ALS NEW YORK, Nov. 7, 2022...

Biomarker analyses show robust increases in cerebrospinal fluid neuroprotective biomarkers following NurOwn treatment NEW YORK, Oct. 20, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc....

NurOwn® drove biomarker responses, affecting pathways related to neurodegeneration, neuroinflammation, and neuroprotection, that were consistent in participants with both advanced ALS and less...

Data demonstrate NurOwn's safety and provide preliminary evidence of efficacy in patients with progressive multiple sclerosis Biomarker analyses show consistent treatment effects in...

BrainStorm to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for NurOwn® for the treatment of ALS New clinical analyses reinforce the conclusions from...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update...

Analyses accounting for ALSFRS-R floor effect in ALS yields new results to be presented at the ENCALS meeting in Edinburgh, Scotland Clinical, biomarker and preclinical data from NurOwn® Phase 2...

BrainStorm continues to gain insights and perspectives from leading ALS experts as it seeks the optimal path forward to provide broad patient access to NurOwn® Strengthened executive team in...

Netta Blondheim-Shraga, PhD Appointed as VP R&D Antal Pearl-Lendner, Adv. Appointed as Chief Legal Counsel NEW YORK, May 12, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI),...

NurOwn-derived exosomes showed more potent anti-inflammatory effects in vitro compared to naïve mesenchymal stem cell-derived exosomes NEW YORK, May 4, 2022 /PRNewswire/ -- BrainStorm Cell...

Data on MSC-NTF exosome technology at ISCT 2022 and ISEV 2022 conferences NurOwn® CFS biomarker analysis to be presented at ALS Drug Development Summit NEW YORK, May 3, 2022 /PRNewswire/ --...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update...

Brainstorm Cell Therapeutics (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative disease, announced today that the company President and Chief Medical Officer, Ralph...

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the fiscal year...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptance of a scientific abstract as a...